The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia DOI Creative Commons
Helga Zoëga, Michael O. Falster, M. Gillies

et al.

Pharmacoepidemiology and Drug Safety, Journal Year: 2024, Volume and Issue: 33(8)

Published: Aug. 1, 2024

ABSTRACT Background The Medicines Intelligence (MedIntel) Data Platform is an anonymised linked data resource designed to generate real‐world evidence on prescribed medicine use, effectiveness, safety, costs and cost‐effectiveness in Australia. Results platform comprises Medicare‐eligible people who are ≥18 years residing New South Wales (NSW), Australia, any time during 2005–2020, with administrative dispensed prescription medicines (Pharmaceutical Benefits Scheme), health service use (Medicare Schedule), emergency department visits (NSW Emergency Department Collection), hospitalisations Admitted Patient Collection) plus death (National Death Index) cancer registrations Cancer Registry). currently available 2022, approval update the cohort collections annually. includes 7.4 million unique across all years, covering 36.9% of Australian adult population; overall population increased from 4.8 M 2005 6.0 2020. As 1 January 2019 (the last pre‐pandemic year), had a mean age 48.7 (51.1% female), most (4.4 M, 74.7%) major city. In 2019, 4.4 (73.3%) were medicine, 1.2 (20.5%) hospitalised, 5.3 (89.4%) GP or specialist appointment, 54 003 died. Anti‐infectives prevalent (43.1%), followed by nervous system (32.2%) cardiovascular (30.2%). Conclusion MedIntel creates opportunities for national international research collaborations enables us address contemporary clinically‐ policy‐relevant questions about quality outcomes Australia globally.

Language: Английский

Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study DOI Creative Commons
Jialing Lin, Tamara Y. Milder, Claire T. Deakin

et al.

Diabetes Research and Clinical Practice, Journal Year: 2025, Volume and Issue: 224, P. 112242 - 112242

Published: May 9, 2025

Language: Английский

Citations

0
The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia DOI Creative Commons
Helga Zoëga, Michael O. Falster, M. Gillies

et al.

Pharmacoepidemiology and Drug Safety, Journal Year: 2024, Volume and Issue: 33(8)

Published: Aug. 1, 2024

ABSTRACT Background The Medicines Intelligence (MedIntel) Data Platform is an anonymised linked data resource designed to generate real‐world evidence on prescribed medicine use, effectiveness, safety, costs and cost‐effectiveness in Australia. Results platform comprises Medicare‐eligible people who are ≥18 years residing New South Wales (NSW), Australia, any time during 2005–2020, with administrative dispensed prescription medicines (Pharmaceutical Benefits Scheme), health service use (Medicare Schedule), emergency department visits (NSW Emergency Department Collection), hospitalisations Admitted Patient Collection) plus death (National Death Index) cancer registrations Cancer Registry). currently available 2022, approval update the cohort collections annually. includes 7.4 million unique across all years, covering 36.9% of Australian adult population; overall population increased from 4.8 M 2005 6.0 2020. As 1 January 2019 (the last pre‐pandemic year), had a mean age 48.7 (51.1% female), most (4.4 M, 74.7%) major city. In 2019, 4.4 (73.3%) were medicine, 1.2 (20.5%) hospitalised, 5.3 (89.4%) GP or specialist appointment, 54 003 died. Anti‐infectives prevalent (43.1%), followed by nervous system (32.2%) cardiovascular (30.2%). Conclusion MedIntel creates opportunities for national international research collaborations enables us address contemporary clinically‐ policy‐relevant questions about quality outcomes Australia globally.

Language: Английский

Citations

1